[Management of immune-related adverse events (irAEs) - what needs to be respected?] / Nebenwirkungsmanagement immunonkologischer Therapien was gibt es zu beachten?
Gynakologe
; 55(5): 344-350, 2022.
Article
en De
| MEDLINE
| ID: mdl-35494537
ABSTRACT
The principles of immuno-oncology treatment have different spectra of side effects. In addition to acute treatment-related adverse events (AE), which sometimes lead to termination of treatment, there are also AEs that can occur after a latent time period, even long after discontinuation of the immuno-oncology agents, for example autoimmune reactions. Monitoring with respect to immune-related adverse events (irAE) is essential. It is decisive to estimate and grade the severity of possible AEs as well as to consider and exclude other differential diagnoses. The grading of the degree of severity of AEs using the Common Terminology Criteria for Adverse Events scale, is followed by clinical therapeutic reactions and consequences when necessary.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
De
Año:
2022
Tipo del documento:
Article